Press releases

The FARAPULSE PFA System now approved for pulmonary vein and posterior wall ablation in patients with persistent atrial fibrillation

Boston Scientific Corporation (NYSE: BSX) will webcast its conference call discussing financial results and business highlights for the second quarter ended June 30, 2025, on Wednesday, July 23,...

Boston Scientific will participate in two upcoming investor conferences in May 2025. A live webcast and replay will be available for each event. Read more.

Trial achieves positive results in the treatment of persistent atrial fibrillation.

After 30 successful years with Boston Scientific, Dan will work closely with CFO successor Jon Monson to ensure a smooth transition.

"We delivered an exceptional quarter to start the year,” said Mike Mahoney, chairman and CEO, Boston Scientific.

Boston Scientific will webcast its conference call with financial results and business highlights for Q1 ended March 31, 2025. Learn how to tune in.

Acquisition to expand Interventional Cardiology Therapies offerings with ultrasound-based renal denervation therapy for treatment of hypertension

Boston Scientific Corporation (the "Company") (NYSE: BSX) today announced that American Medical Systems Europe B.V. ("AMS Europe"), its wholly owned finance subsidiary, has completed a public...

Boston Scientific Corporation (NYSE: BSX) announced the pricing of a public offering of senior notes.